Right to Make Transmittable

METALLA AND NOVA ANNOUNCE COMPLETION OF ARRANGEMENT

Retrieved on: 
Friday, December 1, 2023
Funding, TSX Venture Exchange, NYSE, Acquisition, LLP, Metalla, Serres, DLA Piper, MTA, BMO Capital Markets, Dorsey & Whitney, Model Business Corporation Act, Blake, Cassels & Graydon, Letter, Amend, Consideration, Arrangement, Subscription business model, Computershare, Loan, Legislation, Security (finance), Bank, Commercial property, Metalla, Right to Make Transmittable

Under the terms of the Arrangement, each former shareholder of Nova (a "Nova Shareholder") received 0.36 of a common share of Metalla (each whole share, a "Metalla Share") for each Nova Share held immediately prior to the completion of the Arrangement (the "Consideration").

Key Points: 
  • Under the terms of the Arrangement, each former shareholder of Nova (a "Nova Shareholder") received 0.36 of a common share of Metalla (each whole share, a "Metalla Share") for each Nova Share held immediately prior to the completion of the Arrangement (the "Consideration").
  • Pursuant to the Arrangement, Nova options became immediately vested, and such Nova options have been exchanged for replacement options exercisable for Metalla Shares at the same conversion ratio applicable to the Nova Shares, and any certificate or option agreement previously evidencing Nova options now evidences (and shall be deemed to evidence) such replacement options.
  • for those that ceased to be an employee, consultant, ‎officer or director of Nova or Metalla, as the case may be), provided that in no case shall the ‎date of expiry of any replacement option extend beyond the date that is 10 years from ‎the date of grant of the original Nova option.‎
    Pursuant to the Arrangement, each restricted share unit of Nova that was outstanding immediately prior to completion of the Arrangement ("Nova RSU") was deemed to be fully vested and settled in Nova Shares, which Nova Shares participated in the Arrangement.
  • The consideration that a holder of Nova RSUs is entitled to receive under the Arrangement may be subject to tax withholdings in accordance with the Arrangement.

SPHINX INVESTEMENT CORP. ANNOUNCES EXTENSION OF TENDER OFFER TO PURCHASE ALL OUTSTANDING COMMON SHARES AND ASSOCIATED RIGHTS OF PERFORMANCE SHIPPING INC.

Retrieved on: 
Monday, October 30, 2023
Transfer, BY, Security (finance), Tender, Tata Investment Corp, TIME, Restatements of the Law, Offer, Maryport, Indian stock exchange, EACH, Letter of transmittal, Sixth Amendment of the Constitution of India, Letter, ARE, Schedule, Personal Information Agent, Cryptocurrency, Right to Make Transmittable, Performance

The expiration date of the Offer has been extended to 11:59 p.m., New York City time, on November 15, 2023.

Key Points: 
  • The expiration date of the Offer has been extended to 11:59 p.m., New York City time, on November 15, 2023.
  • 1 thereto on October 30, 2023 (including the Offer to Purchase and the Letter of Transmittal) (the "Tender Offer Materials").
  • A solicitation and offer to purchase outstanding Shares is only being made pursuant to the Tender Offer Materials.
  • The Tender Offer Materials may be obtained at no charge at the website maintained by the Securities and Exchange Commission at www.sec.gov .

Golden Minerals to Effect 1-for-25 Reverse Stock Split

Retrieved on: 
Tuesday, May 30, 2023
Mining, Minerals, Natural Resources, Exercise, State, Letter, Right to Make Transmittable, EDT, NYSE, NYSE American, Computershare, TSX, CUSIP, Toronto Stock Exchange, United Western Minerals Company, Book, Security (finance), Golden

Golden Minerals Company (“Golden Minerals,” “Golden” or the “Company”) (NYSE-A: AUMN and TSX: AUMN) announced today that at its annual meeting of stockholders held on May 26, 2023, its stockholders approved a reverse stock split of the Company’s common stock.

Key Points: 
  • Golden Minerals Company (“Golden Minerals,” “Golden” or the “Company”) (NYSE-A: AUMN and TSX: AUMN) announced today that at its annual meeting of stockholders held on May 26, 2023, its stockholders approved a reverse stock split of the Company’s common stock.
  • The board today announced it has selected a reverse stock split ratio of 1-for-25 shares.
  • When the reverse stock split becomes effective, every 25 shares of the Company’s issued shares of common stock will be combined into one share of common stock without any action on the part of the Company or its stockholders.
  • The reverse stock split will affect all stockholders uniformly and, as of the effective date, each stockholder will own a reduced number of shares of common stock.

Bluegreen Vacations Holding Corporation Announces Amendment of Tender Offer to Increase Offer Price to $25.00 per Share and Extend Tender Offer Until December 23, 2022

Retrieved on: 
Monday, December 12, 2022
Commercial Building & Real Estate, Other Travel, Construction & Property, Lodging, Destinations, Travel, Vacation, Residential Building & Real Estate, Transfer, Security (finance), Letter, Schedule, Annual report, Common stock, Letter of transmittal, NYSE, Compte rendu, BVH, Cryptocurrency, Right to Make Transmittable

American Stock Transfer & Trust Company, LLC is acting as the depositary for the tender offer.

Key Points: 
  • American Stock Transfer & Trust Company, LLC is acting as the depositary for the tender offer.
  • Laurel Hill Advisory Group, LLC is serving as information agent for the tender offer.
  • Copies of the tender offer documents and requests for assistance may be directed to the information agent toll-free at (888) 742-1305.
  • The Companys Board of Directors has authorized the Company to make the tender offer and approved the amendment and extension of the tender offer described in this press release.

Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine

Retrieved on: 
Monday, October 3, 2022
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Nephrology, Gene editing, Letter, Gene, RESPECT, Failure, AstraZeneca, U.S. Securities and Exchange Commission, Therapy, Communication, Security (finance), Acquisition, Tissue, DNA, Degenerative disease, NASDAQ, Immunology, Research, Nature, Ophthalmology, Centerview Partners, Science, Patient, Capsid, Schedule, Time, SEC, Lists of diseases, LLC, Forward-looking statement, Risk, Cardiology, Paul, Weiss, Rifkind, Wharton & Garrison, Metabolism, Technology, AAV, Biopharmaceutical, Alexion Pharmaceuticals, Neurology, Uncertainty, Pharmaceutical industry, Vaccine, Risk management, Alexion, Right to Make Transmittable

Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

Key Points: 
  • Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
  • The proposed acquisition aims to rapidly accelerate Alexions growth in genomic medicines through LogicBios unique technology, experienced rare disease R&D team, and expertise in pre-clinical development.
  • "The proposed acquisition of LogicBio is a significant development for our growing research in genomic medicine, said Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease.
  • LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

Retrieved on: 
Friday, August 5, 2022
Oncology, Professional Services, Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, MAKE, Electric Bond and Share Company v. Securities and Exchange Commission, Telephone, HSR, Letter, Schedule, CVR, SEC, EACH, Achievement, Research, Communication, Hart–Scott–Rodino Antitrust Improvements Act, AND, PARTIES, Compulsory purchase laws in Scotland, Computershare, TIME, SAS, Personal Information Agent, IPN, NASDAQ, Tender, Ipsen, Heart, THE, ADR, Right to Make Transmittable, Security (finance), Cryptocurrency, Euronext, Share (finance), Neuroscience

The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022.

Key Points: 
  • The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022.
  • Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer.
  • The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO (including an Offer to Purchase, a related Letter of Transmittal and certain other tender offer documents) filed by Purchaser, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS and Ipsen S.A. with the SEC on July 12, 2022, as amended or supplemented from time to time.
  • The tender offer materials and the Solicitation/Recommendation Statement are available free of charge at the SECs website at www.sec.gov .

Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

Retrieved on: 
Tuesday, July 19, 2022
Biotechnology, Pharmaceutical, Health, SEC, Right to Make Transmittable, BMY, Acquisition, U.S. Securities and Exchange Commission, Letter, Bristol Myers Squibb, EACH, Patient, LinkedIn, Agreement, Communication, TIME, BY, Tender, Securities Exchange Act of 1934, Forward-looking statement, NYSE, Schedule, Twitter, 14th Floor Records, Eastern Time Zone, Turning Point, Securities Act of 1933, Plan, NASDAQ, Sumathi Best Television Current Reporting Award, Instagram, Risk, Tax, Annual report, YouTube, AND, Corporation, Common stock, Cryptocurrency, Pharmaceutical industry, Facebook

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Offeror filed with the SEC.

Key Points: 
  • This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Offeror filed with the SEC.
  • At the time the tender offer was commenced, Bristol Myers Squibb caused Offeror to file a tender offer statement on Schedule TO and Turning Point filed a recommendation statement on Schedule 14D-9.
  • You may read any reports, statements or other information filed by Bristol Myers Squibb or Turning Point with the SEC at no charge on the SECs website at www.sec.gov .
  • Neither Bristol Myers Squibb nor Turning Point undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Regional Health Properties, Inc. Reminds Common Shareholders of Upcoming Special Meeting and Encourages Common Shareholders to Vote

Retrieved on: 
Friday, July 15, 2022
Nursing, Commercial Building & Real Estate, Construction & Property, Other Health, Health, General Health, Public Relations, Investor Relations, Seniors, Communications, Hospitals, Consumer, Transfer, SEC, 2015 Michigan Proposal 1, RHE, Section 10 of the Canadian Charter of Rights and Freedoms, Reading, U.S. Securities and Exchange Commission, Acquisition, Institutional Shareholder Services, THE, Prospectus, Special, Person, Board of directors, Communication, Proxy, Personal Information Agent, NYSE, Schedule, General number field sieve, AS, Eastern Time Zone, SNF, Securities Act of 1933, Exchange, Form, Board, Sale, Company, ANY, Letter, AND, Annual general meeting, Exchange offer, Director, Holding company, Security (finance), Medical device, Right to Make Transmittable

Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (RHE, we or the Company) reminds its common shareholders to vote at the upcoming special meeting (the Special Meeting) to be held on Monday, July 25, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia.

Key Points: 
  • Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (RHE, we or the Company) reminds its common shareholders to vote at the upcoming special meeting (the Special Meeting) to be held on Monday, July 25, 2022 at 10:00 a.m., Eastern Time, at Sonesta Gwinnett Place Atlanta, located at 1775 Pleasant Hill Road, Duluth, Georgia.
  • Institutional Shareholder Services (ISS), a leading independent proxy advisory firm, has recommended that common shareholders vote FOR the above Proposals 1 and 2.
  • RHE filed the definitive proxy statement/prospectus (as supplemented or amended) in connection with the proposed transaction with the SEC.
  • Investors should read the definitive proxy statement/prospectus carefully before making any voting or investment decisions.

Western Metals Corporation Announces Tender Offer for Common Stock

Retrieved on: 
Friday, July 8, 2022
Energy, Natural Resources, Mining, Minerals, Oil, Gas, Offer, OTC, Tripura Merger Agreement, Right to Make Transmittable, Chapter 13, Title 11, United States Code, African Metals Corporation, Board of directors, Letter, Letter of transmittal, Company, Expiration, Computershare, Person, LLC, TD Bank, N.A., Share, Time, Sub, Board, WTLC, Security (finance), Lease, Holding company, Parent, Mergers and acquisitions, Share (finance)

The initial scheduled expiration time of the Offer is 5:00 p.m., New York City time (the Offer Expiration Time), on August 10, 2022, unless the Offer is extended as described in the Offer to Purchase.

Key Points: 
  • The initial scheduled expiration time of the Offer is 5:00 p.m., New York City time (the Offer Expiration Time), on August 10, 2022, unless the Offer is extended as described in the Offer to Purchase.
  • Another 20.66% of issued and outstanding Shares are owned by persons related to or associated with Parent and its owners.
  • Neither director representative of a Parent Owner voted for or against the Offer.
  • The Offer to Purchase, the related Letter of Transmittal and other related documents are being distributed to the Companys Shareholders.

JetBlue Welcomes Support for Superior Offer to Acquire Spirit

Retrieved on: 
Tuesday, June 28, 2022
Air, Transport, Other Travel, Transportation, Destinations, Travel, Other Transport, Annual report, Acquisition, Securities Exchange Act of 1934, Securities Act of 1933, Right to Make Transmittable, Travel, Fortification, U.S. Securities and Exchange Commission, Behavior, Hearing, Letter, SPIRIT, Disease, JBLU, Public health, Forward-looking statement, TIG, BLUE, ISS, Institutional Shareholder Services, ALL, NYSE, Private Securities Litigation Reform Act, SEC, City, NASDAQ, Ouija, Coronavirus, Management, Security (finance), Auction, JetBlue, Frontier, Spirit

JetBlue (NASDAQ: JBLU) today welcomed the recent public support in favor of its clearly superior offer to acquire Spirit (NYSE: SAVE).

Key Points: 
  • JetBlue (NASDAQ: JBLU) today welcomed the recent public support in favor of its clearly superior offer to acquire Spirit (NYSE: SAVE).
  • At the same time, the addition of the ticking fee in the JetBlue offer a provision without a counterpart in the Frontier offer provides a further level of regulatory risk mitigation.
  • Our decisively superior offer is being recognized by Spirit shareholders and proxy advisors as providing more for Spirit shareholders than the ill-fated Frontier merger, which the conflicted Spirit Board has entered into, said Robin Hayes, chief executive officer, JetBlue.
  • Shareholders can send a clear message to the Spirit Board by voting No at the upcoming Spirit special meeting.